Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 4/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998575 | 1.00 | SLC9A1 (0.38) | SLC9A1CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL5090958 | 0.82 | PGR (0.38) | CYP2C19PGRRBP4CHRM2CHRM1 | |
| SCHEMBL5091095 | 0.81 | PGR (0.38) | CYP2C19PGRRBP4CHRM2CHRM1 | |
| SCHEMBL5090995 | 0.79 | HSD17B1 (0.46) | SLC9A1CYP2C9CYP2C19CYP3A4KCNH2 | |
| SCHEMBL5103709 | 0.77 | GPR142 (0.40) | PGRRBP4 | |
| SCHEMBL5103257 | 0.74 | RBP4 (0.35) | PGRRBP4CHRM2CHRM1CHRM3 | |
| SCHEMBL13711484 | 0.74 | CHRM2 (0.38) | FFAR2CHRM2CHRM1CHRM3 | |
| SCHEMBL5091903 | 0.73 | MEN1 (0.37) | PGRRBP4CHRM2CHRM1CHRM3 | |
| SCHEMBL3963938 | 0.70 | SETD7 (0.31) | FFAR2 | |
| SCHEMBL13627442 | 0.70 | SETD7 (0.31) | FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | SLC9A1 3661/4885CYP2C9 322/4885CYP2C19 319/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | SLC9A1 3661/4885CYP2C9 322/4885CYP2C19 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.